BTIG on Aldeyra Therapeutics (ALDX): CRL 'hard to defend,' path to clarity within 90 days

March 17, 2026 4:08 PM

BTIG analyst Thomas Shrader reiterated a Buy rating and $9.00 price target on Aldeyra Therapeutics (NASDAQ: ALDX)The analyst commented, "Another ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found